Vanda Pharmaceuticals Inc. v. Alembic Pharmaceuticals Limited
1:26-cv-00905
Overview
Parties
Defendant
Alembic Pharmaceuticals, Inc. Operating Company
Represented By
0 Attorneys ListedAlembic Pharmaceuticals Limited NPE (University / Research)
Represented By
0 Attorneys ListedPlaintiff
Vanda Pharmaceuticals Inc. Operating Company
Represented By
2 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 5 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 8,586,610 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 61,479,804 P | US Continuation / Sibling | View Official Patent → |
| π PCT International (WIPO) | WO 2006039663 A2 | PCT World Application | View Official Patent → |
| πΊπΈ United States | US 2010006309 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2014004589 | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8586610
Methods for the administration of iloperidone
|
Filed: 2005-09-30
Issued: 2013-11-19
|
Active (1.0 yrs remaining)
+763d PTA
Expires: 2027-11-02
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
High PTA (+763 days) / Cellect Scrutiny β Over 763 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
2
Dispositive
0
Granted
0
Denied
0
Pending / Review
2
Motions by Category
Key Dispositive Motions & Rulings